GlassScriptPhysician profile
Sandra D Lithgow
NPI 1205933033
$4,031.79
in general payments reported to CMS, 2019-2025
26 companies · $837 in 2025
The $837 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $280 · 2020: $147 · 2021: $404 · 2022: $371 · 2023: $1,047 · 2024: $946 · 2025: $837.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,765 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,764.87 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,270.88 | 2021-2025 | |
| Pfizer INC. | $742.44 | 2021-2025 | |
| Novo Nordisk INC | $702.51 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $218.53 | 2019-2025 | Xifaxan |
| Exact Sciences Corporation | $178.16 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $126.17 | 2019-2024 | Breztri, Farxiga |
| Glaxosmithkline, LLC. | $124.98 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $119.70 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Allergan, INC. | $58.30 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $52.68 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $51.76 | 2019-2021 | |
| Sanofi Pasteur INC. | $41.75 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.10 | 2019-2020 | |
| Amgen INC. | $36.85 | 2024-2025 | Repatha, Enbrel |
| Phadia US INC. | $35.52 | 2023-2025 | Immunocap |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $30.47 | 2024 | Haegarda |
| Genentech USA, INC. | $29.34 | 2019-2020 | |
| Antares Pharma, INC. | $27.05 | 2024 | Xyosted |
| Horizon Therapeutics Plc | $26.37 | 2023 | Krystexxa |
| Halozyme INC | $23.44 | 2023 | |
| Astellas Pharma US INC | $21.59 | 2019 | |
| Seqirus USA INC | $21.22 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Medtronic USA, INC. | $14.64 | 2020 | |
| Lilly USA, LLC | $13.76 | 2025 | Zepbound, Mounjaro |
| Amarin Pharma, INC. | $12.18 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Lithgow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.